The research grade product, pALD-AAV6 is immediately available at the good manufacturing practice (GMP) source quality level, while pALD-AAV2 and pALD-AAV5 will be made available based on market demand. These products are designed to support preclinical activities through clinical development and commercial production, according to Aldevron.

"Along with offering catalog items, we have increased capacity and reduced lead times, providing us the ability to scale while meeting important client deadlines," Michelle Berg, president of Aldevron's GMP nucleic acids business unit.

Genprex expands gene therapy manufacturing
Genprex has expanded its program to manufacture tumor suppressor candidate 2 (TUSC2) with a new manufacturing agreement with partner Aldevron.